Page 69 - Haematologica-April 2018

MPN patients’ non-adherence to treatment
ence would be necessary to confirm these observations. This evaluation will be not possible with our cohort, since after the blinding had been removed, all treatment non-adherent patients were managed to improve their adherence. Larger multicenter studies could confirm the “non-adherent profile” which sometimes pointed to unexpected findings, such as taller height in male patients not adhering fully with treatment.
To our knowledge, OUEST is the first study on the inci- dence, determinants and impact of treatment non-adher- ence on the outcome of patients with Philadelphia nega- tive MPN. The occurrence of non-adherence is relatively common, with an incidence of 28%, but is generally mod- erate. Younger age and the route and schedule of drug
administration seem to be the major determinants of poor treatment adherence. Phenotypic evolution seems to be more frequent in the group not adherent to treatment, suggesting that cytoreductive drug pressure could help to reduce the risk of evolution. Major efforts should be invested into improving treatment adherence.
Acknowledgments
The authors would like to thank all the patients who took the time to complete the questionnaire as a mark of interest in this study. The authors would also like to thank the France Intergroup of Myeloproliferative neoplasms (FIM) for its help with this study: RLC, VU, SG, EL and JCI are members of this cooperative group.
References
1. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloprolif- erative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761-770.
2. Sabaté E, World Health Organization, edi- tors. Adherence to long-term therapies: evi- dence for action. Geneva: World Health Organization; 2003,p.198.
3. Salmeron S, Liard R, Elkharrat D, Muir J, Neukirch F, Ellrodt A. Asthma severity and adequacy of management in accident and emergency departments in France: a prospective study. Lancet. 2001;358 (9282):629-635.
4. Söderlund S, Dahlén T, Sandin F, et al. Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish
CML register. Eur J Haematol. 2017;98(1):57-66.
5. Santoleri F, Lasala R, Ranucci E, et al. Medication adherence to tyrosine kinase inhibitors: 2-year analysis of medication adherence to imatinib treatment for chron- ic myeloid leukemia and correlation with the depth of molecular response. Acta Haematol. 2016;136(1):45-51.
6. Marin D, Bazeos A, Mahon F-X, et al. Adherence is the critical factor for achiev-
ing molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on ima- tinib. J Clin Oncol. 2010;28(14):2381-2388.
7. Noens L, van Lierde M-A, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113(22): 5401-5411.
8. Noens L, Hensen M, Kucmin-Bemelmans I, Lofgren C, Gilloteau I, Vrijens B. Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges. Haematologica. 2014;99(3): 437-447.
9. Bhatia S, Landier W, Hageman L, et al. 6MP adherence in a multiracial cohort of chil- dren with acute lymphoblastic leukemia: a Children’s Oncology Group study. Blood. 2014;124(15):2345-2353.
10. Cortes JE, Egorin MJ, Guilhot F, Molimard M, Mahon FX. Pharmacokinetic/ pharma- codynamic correlation and blood-level test- ing in imatinib therapy for chronic myeloid leukemia. Leukemia. 2009;23(9):1537-1544.
11. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487- 497.
12. Candrilli SD, O’Brien SH, Ware RE, Nahata MC, Seiber EE, Balkrishnan R. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with
sickle cell disease. Am J Hematol. 2011;86
(3):273–277.
13. Amitai I, Leader A, Raanani P. Adherence
to tyrosine kinase inhibitors in chronic myeloid leukemia: the challenge that lies ahead. Acta Haematol. 2016;136(1):43-44.
14. Cuisset T, Quilici J, Fugon L, et al. Non- adherence to aspirin in patients undergoing coronary stenting: negative impact of comorbid conditions and implications for clinical management. Arch Cardiovasc Dis. 2011;104(5):306-312.
15. Schwartz KA, Schwartz DE, Ghosheh K, Reeves MJ, Barber K, DeFranco A. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarc- tion. Am J Cardiol. 2005;95(8):973-975.
16. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333(7557):15.
17. Casini A, Fontana P, Lecompte TP. Thrombotic complications of myeloprolif- erative neoplasms: risk assessment and risk-guided management. J Thromb Haemost. 2013;11(7):1215-1227.
18. Masarova L, Patel KP, Newberry KJ, et al. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or poly- cythaemia vera: a post-hoc, median 83 months follow-up of an open-label, phase 2 trial. Lancet Haematol. 2017;4(4):e165- e175.
haematologica | 2018; 103(4)
613